Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,940 | 3 | 53.1% |
| Consulting Fee | $3,004 | 3 | 20.1% |
| Travel and Lodging | $2,597 | 7 | 17.4% |
| Food and Beverage | $1,194 | 15 | 8.0% |
| Education | $153.02 | 4 | 1.0% |
| Gift | $59.40 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $10,635 | 13 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,413 | 2 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,283 | 2 | $0 (2023) |
| Tandem Diabetes Care, Inc. | $1,004 | 5 | $0 (2022) |
| Horizon Therapeutics plc | $252.91 | 3 | $0 (2023) |
| Corcept Therapeutics | $154.46 | 3 | $0 (2024) |
| Companion Medical, Inc. | $60.74 | 1 | $0 (2019) |
| MannKind Corporation | $59.40 | 1 | $0 (2018) |
| Medtronic MiniMed, Inc. | $40.85 | 1 | $0 (2017) |
| Amgen Inc. | $30.68 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $60.75 | 1 | Corcept Therapeutics ($60.75) |
| 2023 | $1,945 | 5 | Novo Nordisk Inc ($1,740) |
| 2022 | $1,403 | 3 | Bayer HealthCare Pharmaceuticals Inc. ($1,264) |
| 2021 | $69.87 | 2 | Horizon Therapeutics plc ($36.91) |
| 2019 | $1,059 | 7 | Tandem Diabetes Care, Inc. ($956.02) |
| 2018 | $72.66 | 2 | MannKind Corporation ($59.40) |
| 2017 | $10,335 | 13 | Novo Nordisk Inc ($8,882) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/25/2024 | Corcept Therapeutics | Korlym (Drug) | Education | In-kind items and services | $60.75 | General |
| Category: Endocrinology | ||||||
| 12/05/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $870.00 | General |
| 11/27/2023 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $870.00 | General |
| 10/05/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: TEPEZZA | ||||||
| 08/10/2023 | Corcept Therapeutics | Korlym (Drug) | Education | In-kind items and services | $60.75 | General |
| Category: Endocrinology | ||||||
| 05/03/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Education | In-kind items and services | $19.62 | General |
| Category: Cardio-renal | ||||||
| 11/08/2022 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | Cash or cash equivalent | $48.20 | General |
| Category: Endocrinology | ||||||
| 09/21/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $1,263.50 | General |
| Category: Cardio-renal | ||||||
| 04/27/2022 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $91.00 | General |
| Category: TEPEZZA | ||||||
| 11/17/2021 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $32.96 | General |
| Category: Endocrinology | ||||||
| 03/04/2021 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $36.91 | General |
| Category: TEPEZZA | ||||||
| 09/07/2019 | Tandem Diabetes Care, Inc. | t-slim insulin pump (Device) | Food and Beverage | Cash or cash equivalent | $20.10 | General |
| Category: Endocrinology | ||||||
| 09/06/2019 | Tandem Diabetes Care, Inc. | t-slim insulin pump (Device) | Travel and Lodging | Cash or cash equivalent | $792.35 | General |
| Category: Endocrinology | ||||||
| 09/06/2019 | Tandem Diabetes Care, Inc. | t-slim insulin pump (Device) | Food and Beverage | Cash or cash equivalent | $115.68 | General |
| Category: Endocrinology | ||||||
| 09/06/2019 | Tandem Diabetes Care, Inc. | t-slim insulin pump (Device) | Travel and Lodging | Cash or cash equivalent | $27.89 | General |
| Category: Endocrinology | ||||||
| 08/26/2019 | Companion Medical, Inc. | InPen (Device) | Food and Beverage | In-kind items and services | $60.74 | General |
| Category: Diabetes | ||||||
| 07/17/2019 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $30.68 | General |
| Category: Bone Health | ||||||
| 01/04/2019 | EISAI INC. | Belviq (Drug) | Education | Cash or cash equivalent | $11.90 | General |
| Category: Nutrition and Weight Loss | ||||||
| 08/28/2018 | MannKind Corporation | AFREZZA (Drug) | Gift | In-kind items and services | $59.40 | General |
| Category: DIABETES MEDICINE | ||||||
| 08/15/2018 | Novo Nordisk Inc | FIASP (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Diabetes | ||||||
| 07/06/2017 | Medtronic MiniMed, Inc. | Minimed 670G System (Device) | Food and Beverage | In-kind items and services | $40.85 | General |
| Category: Durable Pump | ||||||
| 05/08/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/28/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/20/2017 | Novo Nordisk Inc | Victoza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,900.00 | General |
| Category: Diabetes | ||||||
| 03/20/2017 | Novo Nordisk Inc | Victoza (Drug) | Travel and Lodging | In-kind items and services | $627.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 657 | 2,578 | $152,907 | $91,692 |
| 2022 | 11 | 787 | 8,077 | $275,461 | $183,888 |
| 2021 | 14 | 802 | 9,148 | $263,808 | $182,270 |
| 2020 | 12 | 758 | 7,592 | $238,529 | $152,132 |
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 259 | 438 | $57,816 | $37,586 | 65.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 27 | 1,620 | $35,640 | $26,716 | 75.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 103 | 103 | $23,690 | $11,755 | 49.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 83 | 175 | $10,675 | $4,416 | 41.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 29 | $5,452 | $3,560 | 65.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $4,800 | $1,859 | 38.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 34 | $2,958 | $1,807 | 61.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 49 | 86 | $4,214 | $1,429 | 33.9% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 13 | 13 | $3,523 | $1,231 | 34.9% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 11 | 11 | $2,519 | $768.79 | 30.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 38 | 54 | $1,620 | $564.30 | 34.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 91 | 7,020 | $154,440 | $117,911 | 76.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 282 | 472 | $62,304 | $39,169 | 62.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 55 | $10,340 | $6,375 | 61.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 59 | 59 | $13,570 | $6,171 | 45.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 70 | 141 | $8,601 | $3,531 | 41.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $5,440 | $2,614 | 48.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 46 | $4,002 | $2,394 | 59.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 49 | 96 | $4,704 | $1,484 | 31.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 95 | 138 | $4,140 | $1,473 | 35.6% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 20 | 20 | $4,397 | $1,469 | 33.4% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2022 | 13 | 13 | $3,523 | $1,296 | 36.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 90 | 8,100 | $147,840 | $115,258 | 78.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 282 | 465 | $61,380 | $41,876 | 68.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 57 | $10,716 | $7,089 | 66.1% |
About Dr. Eric Orth, DO
Dr. Eric Orth, DO is a Endocrinology, Diabetes & Metabolism healthcare provider based in Bloomington, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255398202.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Orth, DO has received a total of $14,946 in payments from pharmaceutical and medical device companies, with $60.75 received in 2024. These payments were reported across 33 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($7,940).
As a Medicare-enrolled provider, Orth has provided services to 3,004 Medicare beneficiaries, totaling 27,395 services with total Medicare billing of $609,982. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Bloomington, IN
- Active Since 04/26/2006
- Last Updated 12/21/2020
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1255398202
Products in Payments
- Victoza (Drug) $3,559
- FARXIGA (Drug) $1,413
- Kerendia (Drug) $1,283
- t-slim insulin pump (Device) $956.02
- TEPEZZA (Drug) $252.91
- Korlym (Drug) $154.46
- InPen (Device) $60.74
- AFREZZA (Drug) $59.40
- t:slim X2 Insulin Pump with Control-IQ (Device) $48.20
- Minimed 670G System (Device) $40.85
- EVENITY (Biological) $30.68
- FIASP (Drug) $13.26
- Belviq (Drug) $11.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Bloomington
Dr. Vijay Kumar, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $20.00
Dr. Philip Behn, M.d, M.D
Endocrinology, Diabetes & Metabolism
Malik Faheem, Md, MD
Endocrinology, Diabetes & Metabolism